◆
Calibrated intranasal delivery of Selank, the benchmark anxiolytic and neuroprotective heptapeptide.

Dose ranges reflect commonly studied amounts in published research models. This is not medical advice. For research use only. Not for human consumption.
Protocol Comparison
Cognitive
Research dose range
Standard research range
200 - 400 mcg
Standard clinical concentration for balanced anxiolysis and stress resistance.
Research focus
Non-sedating anxiolysis & emotional regulation
Observed window
14-21 days active cycle
Administration
1-2 sprays per nostril in research models
Primary pathway
GABA-A allosteric modulation / Enkephalinase inhibition
Dosing derived from published Institute of Molecular Genetics clinical studies. For research use only.
PROTOCOL BENEFITS
◆
Calibrated intranasal delivery of Selank, the benchmark anxiolytic and neuroprotective heptapeptide.
◆
Modulates GABA-A receptor expression, reducing anxiety and stress without sedation or addiction.
◆
Enhances serotonin and dopamine metabolism while supporting enkephalin stability.
SCIENCE
The Selank Nasal Kit utilizes a stabilized synthetic analog of the endogenous immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) extended with Pro-Gly-Pro. Delivered intranasally, it rapidly accesses limbic and cortical structures.
Unlike benzodiazepines, Selank acts as an allosteric modulator of GABA-A receptors, increasing GABAergic affinity without causing tolerance, physical dependence, motor impairment, or sedation.
WHAT TO EXPECT
Anxiolytic and emotional stabilization shifts occur within 15–45 minutes. Sustained mood resilience and cognitive stress adaptation are observed across 2–4 week cycles.
PROTOCOL NOTE
Complete nasal research kit. Strictly for laboratory research.
FAQ
Intranasal was the primary administration route developed for Selank in Russian clinical trials, delivering rapid access to limbic and cortical structures without needles.
A 5 ml solution at 0.05 ml per activation delivers approximately 80–90 consistent sprays after initial priming.